Brief: Novartis AG Discontinues Development Of VHB937 In Amyotrophic Lateral Sclerosis
16/09/2026 17:33
BRIEF-Novartis AG Discontinues Development Of VHB937 In Amyotrophic Lateral Sclerosis Sept 16 (Reuters) - Novartis AG NOVN.S:
NOVARTIS AG: DISCONTINUED DEVELOPMENT OF VHB937 IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) FOLLOWING RESULTS FROM THE PHASE 2 ASTRALS STUDY
NOVARTIS AG: VHB937 DID NOT MEET ITS PRIMARY OR SECONDARY ENDPOINTS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant